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ABSTRACT
EVIDENCE-BASED STRATEGIES TO MINIMIZE RISK FOR
OPIOID PAIN MEDICATION MISUSE AMONG PATIENTS WITH
CHRONIC PAIN IN A PRIMARY CARE SETTING
by Carolyn Diane Coleman
May 2015
Background: Prescription opioid pain medication misuse has become a
nationwide epidemic. Many states have implemented prescription drug monitoring
programs (PDMP) to assist in combating the problem of prescription opioid pain
medication misuse. Evidence-based clinical practice guidelines as well as the PMDP
should be utilized by healthcare providers to guide treatment of chronic pain with opioid
pain medications. Purpose: The purpose of this doctoral capstone project was to
determine if providers are accessing the Prescription Drug Monitoring Program (PDMP)
and utilizing evidence-based guidelines to minimize opioid pain medications misuse
among patients with chronic pain in a primary care setting. Method: This project
consisted of a retrospective chart review of prescribers’ documentation in the medical
record to determine if the PDMP was accessed and if evidence-based protocols were used
when prescribing opioid pain medication to patients diagnosed with chronic pain seen in
a primary care clinic. Results: Seven (N=7) records that met inclusion criteria for the
project were identified for review over a three month time frame. The seven records
were all identified to have been seen by a nurse practitioner. All (N=7; 100%) of the
charts had a history and physical documented. The PDMP was documented to be
accessed on 5 of the 7 records (n=5; 71.4%). Patients were prescribed an opioid pain
ii

medication by the provider less than half (n=3; 42.9%) of the time. Conclusion: This
doctoral capstone project shows that the providers are documenting components of the
history and physical when patients present to a primary care clinic with complaints of
chronic pain. Past history of drug abuse and ordering urine drug screens are evidencebased practice recommendations where prescribers have not documented consistently.
Accessing the PDMP is another area where it shows the prescribers are not consistently
documenting. Implementation of evidence-based guidelines will be imperative in the
fight to minimize risk of misuse of opioid pain medications among patients with chronic
pain in the primary care setting.
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CHAPTER I
INTRODUCTION
Prescription drug misuse is a growing problem in the primary care setting. The
use of prescription drugs in a manner other than as directed is considered drug misuse.
Drug abuse is the use of a prescription drug in a manner that deviates from the approved
medical, legal, or social standards (Federation of State Medical Boards [FSMB], 2004).
When prescription drugs are consumed in an excessive amount and injures the body, it is
considered an overdose (FSMB, 2004). According to the Centers for Disease Control
and Prevention (CDC), deaths from prescription drug overdose have drastically risen over
the past decade and have become the leading cause of death among the different types of
overdoses in the United States (Centers for Disease Control and Prevention [CDC],
2014). With nearly 100 million Americans presenting with the complaints of chronic
pain, according the Institute of Medicine (IOM), pain has become a public challenge
(Institute of Medicine [IOM], 2011). In a response to the 2001 Joint Commission’s
standard on undertreated pain, opioid pain medications began to be prescribed to treat
chronic pain (Broglio & Cole, 2014). Many of these patients present to their primary
care providers who may not have the proper training or tools for managing chronic pain
(Broglio & Cole, 2014). With the increase in opioid pain medication being prescribed for
chronic pain came the misuse of the opioid pain medications (Broglio & Cole, 2014).
Nearly 100 people died of drug overdoses from prescription drug misuse daily in the year
2007, which shows a three-fold increase in the death rate from 1991. (Paulozzi, Jones,
Mack, & Rudd, 2011). Prescription opioid pain medications contribute to prescription
drug misuse because patients will sometimes take doses that are higher than what is
needed in order to obtain a euphoric high (Worley, 2012). Prescription opioid pain
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medications are also sold illegally to persons for whom the medication is not prescribed
for purposes of getting a euphoric high (Worley, 2012).
Opioid pain medications are controlled substances that are subject to special
regulatory requirements under the federal Food and Drug Administration Controlled
Substances Act of 1970 (FSMB, 2004). Opioid pain medications are compounds that
bind to an opioid receptor in the central nervous system and include medications such as
hydrocodone, morphine, fentanyl, or oxycodone (FSMB, 2004). The scheduling of
controlled substances into classes V, IV, III, and II are special regulatory requirements
for prescribing opioid pain medications (U.S. Food and Drug Administration [U.S. FDA],
2009). The special regulatory requirements exist to prevent misuse and abuse of opioid
pain medication prescriptions written for individuals by healthcare providers. Providers
may not have the proper training to manage chronic pain, when chronic pain is one of the
most common reasons patients present to the primary care clinic (Liebschutz & Alford,
2011). Providers in primary care settings prescribe opioid pain medications for
individuals with chronic pain. Misuse of prescribed opioid pain medications is a concern
in primary care settings, especially in the state of Mississippi (Dobbs, Byers, & Fleming,
2013). Many states in the U.S. have utilized Prescription Drug Monitoring Programs
(PDMP) to address the issue of prescription drug misuse. PDMP databases track
controlled substance prescribing by healthcare providers and allow providers to track
prescriptions for opioid pain medications filled by patients and report concerns to the
appropriate law enforcement agencies (Fishman, 2012). The PDMP was implemented to
facilitate the collection, analysis, and reporting of information on the prescribing and
dispensing of controlled substances (FSMB, 2004).
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Although PDMP databases are not a complete solution to the prescription drug
misuse problem, fully funding PDMP so they are real-time, interstate, and incorporated
into the electronic health records (EHR) will identify patients that are doctor shopping
and recognize potential prescription drug abusers (Drug Abuse, 2013). Doctor or
prescriber shopping occurs when patients attempt to obtain controlled substances from
multiple prescribers without the knowledge of the individual prescribers (CDC, 2014).
Healthcare providers that are prescribers of opioid pain medications should utilize tools
such as the PDMPs to identify drug misuse but also implement guidelines to assist with
other methods of pain control when appropriate. Guidelines to steer patients toward
alternative measures should be implemented as a start to combating the problem of
misuse of opioid pain medications. Preventing misuse of prescription drugs by properly
prescribing opioid pain medications for patients with a diagnosis of chronic pain may
lead to improved health outcomes while maintaining proper pain control. As healthcare
delivery moves towards patient-centered and outcomes-based care, combatting this
growing problem of prescription drug misuse will be essential for maintaining wellness in
patients with chronic pain that are seen in primary care settings in Mississippi
Background and Significance
Prescription drug misuse. Prescription drug misuse has become a nationwide
epidemic with deaths quadrupling since 1999 (CDC, 2011). Emergency room visits due
to prescription drug misuse have increased 114% in 2011, with 2.5 million emergency
room visits as a result of drug misuse and 6,748 people treated in emergency departments
daily for the misuse of drugs. Another 1.4 million are treated in emergency departments
for prescription drug misuse (Highlights of DAWN report, 2011). There were 458.3
emergency room visits per 100,000 population due to the misuse of prescription drugs
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with 134.8 visits per 100,000 population due to opioid pain medications in the year 2011
(Highlights of DAWN, 2011). The highest reported emergency room visits in 2011 for
opioid pain medications misuse was due to the misuse of oxycodone (Highlights of
DAWN, 2011).
Adults and teens in community counties as well as soldiers and veterans who
survive serious injuries are at higher risk of misusing prescription drugs and overdosing
(Mississippi State Department of Health [MSDH], 2014). The elderly population
accounts for approximately one quarter of prescription drugs sold in the Unites States
yearly (Culberson & Ziska, 2008); however, it is difficult to estimate the prevalence of
prescription drug misuse among the elderly population. It has been determined that up to
eleven percent of older women misuse and/or abuse prescription drugs (Culberson &
Ziska, 2008). The elderly are more prone to have complaints of chronic pain, insomnia,
and anxiety leading to being treated with prescription drugs. It is also noted that misuse
of prescription pain medication in occupational injuries is becoming an epidemic in
worker’s compensation cases in the state of Mississippi (MSDH, 2014).
Prescription drug overdose and death. An estimated 71,000 children under the
age of 18 years visited an emergency room as a result of prescription medication
overdose between 2004 and 2005 (CDC, 2014). The lowest death rates in the United
States were among children less than 15 years of age due to the fact there are less
incidents of prescription drug use among this age group (CDC, 2014). It is also reported
that 40% of calls reported to the poison centers between 2004 and 2005 for children
under the age of six are related to prescription drug overdose (CDC, 2014). One hundred
and fourteen people died daily in 2011 in the United States as a result of drug overdose
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(Centers for Disease Control and Prevention [CDC], 2014). According to the Centers for
Disease Control and Prevention, deaths from prescription drug overdose have surpassed
traffic-related deaths in 2009 as the leading cause of death in the United States (CDC,
2014). The age of highest death rates for prescription drug misuse in the United States lie
between 45 and 49 years of age and occur among American Indians/Alaska Native,
followed by whites then blacks (CDC, 2014). While these are alarming national statistics
on drug overdose and death, the death rate from the misuse of prescription opioid pain
medications is mainly related to unintentional overdoses of these prescription opioids.
This project will focus on the problem of opioid pain medication misuse among patients
with chronic pain in primary care settings in Mississippi.
Prescription drug misuse, overdose, and deaths in Mississippi
The number of prescription drug overdose deaths in Mississippi, tripled from
1999 to 2013 (Drug Abuse, 2013). Mississippi has the 30th highest prescription drug
overdose mortality rate in the United States, with 11.4 per 100,000 fatalities (Drug abuse,
2013). The number of deaths from unintentional prescription drug overdose in the state of
Mississippi has increased 10-fold since 1990 (MSDH, 2013). The number of deaths have
increased from 23 in 2009 to 232 in 2011(MSDH, 2013). The number of unintentional
prescription drug overdoses have consistently remained the highest in the 45-54 year old
age group in the state of Mississippi (MSDH, 2013).Prescription drug misuse accounted
for 90% of the overdose deaths in Mississippi in 2012, mostly accidental (MSDH, 2014).
While these statistics from various sources using diverse time spans may appear to be
different, the overall message is that the misuse of prescription opioid pain medication
has reached epidemic levels.
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In community health primary care clinics in Mississippi, the misuse of
prescription opioid pain medication is attributed to a ten-fold increase in death (Dobbs, et
al. 2013). In the month of January 2013, there were approximately 180,000 individual
prescriptions for hydrocodone products prescribed in Mississippi with over 10 million
unit doses or pills dispensed (MSDH, 2013). In the state of Mississippi, this large
number of pills would be sufficient to dose every man, woman, and child in the state
more than three doses of hydrocodone during that month (MSDH, 2013). In a response
to the increasing number of prescription controlled substances the state of Mississippi has
implemented a web-based prescription drug monitoring program to monitor the
prescribing and dispensing of controlled substances, such as the opioid pain medications.
Prescription drug monitoring programs. Many states have utilized prescription
drug monitoring programs (PDMP) to address the issue of prescription drug misuse and
state laws have also been implemented to help combat the increasing epidemic of
prescription drug misuse. States have adopted laws such as requiring ID or permitting the
pharmacy to require an ID prior to dispensing controlled substances, expansion for
coverage of substance abuse programs, mandatory usage of prescription drug monitoring
programs by prescribers, and Good Samaritan Laws which give immunity or mitigation
of sentencing to persons seeking help for themselves (Drug abuse, 2013). These laws all
serve as an attempt to decrease mortality rates, decrease the number of individuals who
misuse prescription medications, and deter doctor shopping.
In the state of Mississippi, the PDMP report alerts the prescriber to possible
prescription drug misuse. The PDMP, web-based tool was designed to comply with the
National All Schedules Prescription Electronic Reporting Act of 2005 and is managed
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through the Board of Pharmacy in the state of Mississippi (Dobbs et al., 2013). The
PDMP tracks the number of dosage units, the different providers who have prescribed
opioids to certain patients, and the pharmacies where the patients have had their
prescriptions filled (Dobbs et al., 2013). The Board of Medical Licensure changed its
Administrative code to require all prescribing physicians and physician assistants to be
registered with the PDMP by December 31, 2013 (Dobbs et al., 2013). The MBOML
changes also require educational hours to be completed every two years related to
prescribing, with an emphasis on controlled substances (Dobbs et al., 2013). According
to the positions statement posted to the MS Board of Nursing’s website as of December
2014 the board will require all advanced practice nurses to be registered with the Board
of Pharmacy’s PDMP and recommends usage when prescribing controlled substances
(Mississippi Board of Nursing [MSBN], 2014). Other changes have been implemented to
deter prescription opioid drug abuse. As of October 2014 hydrocodone has been moved
from a scheduled III to schedule II making prescribing excessive amounts less likely and
restricting refills (Dobbs et al., 2013).
Although laws vary widely from state to state, the state of Mississippi scored five
out of ten on the New Policy Report Card of Promising Strategies to Help Curb
Prescription Drug Abuse (Drug abuse, 2013). Mississippi’s regulatory boards have
implemented state regulations that require all prescribers to register with the Board of
Pharmacy’s PDMP. According to the MS State Statues 73-21-127, 73-21-97, and 73-21103, Mississippi has implemented guidelines for PDMP and has an active program
running ("Cumulative supplement to MS code," 2007). Mississippi has also implemented
doctor shopping laws that specify that patients are prohibited from withholding
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information about prior prescriptions from their healthcare providers (Dobbs et al., 2013).
Mississippi also has pharmacy lock-in programs which require patients under the state’s
Medicaid program who are suspected of misusing controlled substances to use a single
prescriber and pharmacy to obtain medications (Dobbs et al., 2013). And lastly,
Mississippi requires or recommends continuing education hours for providers prescribing
opioids (Dobbs et al., 2013). There are also guidelines requiring healthcare providers to
physically examine patients or have a bona fide patient-physician relationship before
prescribing a controlled substance. These steps should be followed when encountering
patients that present to the primary care clinic with complaints of chronic pain.
Accessing the PDMP prior to prescribing prescription opioid pain medications
should alert a prescriber to opioid pain medications that have been obtained from other
prescribers. This project will look at the usage of the PDMP along with evidence-based
practice guidelines for treatment of chronic pain by prescribers in an attempt to minimize
prescription opioid pain medication misuse in a primary care clinic in the state of
Mississippi.
Chronic pain. According to the Institute for Clinical Systems Improvement,
chronic pain is defined as pain without biological value that has persisted beyond the
normal time despite the usual customary efforts to diagnose and treat the original
condition and injury (Hooten et al., 2013). Chronic pain affects at least 116 million
adults in the United States and up to $635 billion each year is spent on medical cost and
lost productivity due to chronic pain (Hooten et al., 2013). In the primary care setting
approximately 5-33% of the patients present with a complaint of chronic pain (Hooten et
al., 2013). Patients with chronic pain present to the primary care clinic with complaints
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of low back pain, headaches, neck pain, and fibromyalgia (Hooten et al., 2013).
Evidence-based clinical practice (EBCP) guidelines for treatment of chronic pain require
prescribers to take a full history and physical and assess functioning when patients
present to the primary care clinic with complaints of pain. EBCP guidelines for treating
pain state the goals for treating pain should include more than prescribing prescription
pain medications, but also measures to improve the patient’s functioning ability (Hooten
et al., 2013).
Prescription pain medication. Opioid pain medications are a class of medications
used to treat chronic pain. The mechanism of action for opioid pain medications is the
opioid compound binds to opioid receptors in the nervous system causing depression of
the nervous system and skeletal muscle relaxations (FSMB, 2004). Adverse effects of
opioid pain medications are nausea, vomiting, sedation, cognitive impairments
respiratory depression, and even death (FSMB, 2004). In addition, opioids have
addiction-forming or addition sustaining liability or are capable of conversion into a drug
having such addiction-forming or addition-sustaining liability (U.S. FDA, 2009).
Indirect and direct healthcare costs related to opioid pain medications are related
to misuse, abuse, addiction, dependence, overdose, and death. In a research of claims
data and other publicly available surveys and secondary sources, Birnbaum et.al looked at
the costs to society of opioid abuse, dependency, and misuse in the United States
(Birnbaum et al., 2011). Costs were grouped in three categories: healthcare, workplace,
and criminal justice (Birnbaum et al., 2011). Workplace costs were approximately $25.6
billion or 46% of the total cost and were driven by lost earnings and reduced
compensations (Birnbaum et al., 2011). Healthcare costs were approximately $25.0
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billion or 45% of the total costs and consisted of medical and prescription costs
(Birnbaum et al., 2011). With criminal costs consisting of $5.1 billion or 9% of the total
costs and were comprised of correctional facility and police costs (Birnbaum et al., 2011).
Data were obtained from private insurance as well as Medicaid claims data. The study
concluded that prescription drug misuse bears a large financial burden on society and as
the prevalence increase the societal economic burdens will also increase (Birnbaum et al.,
2011). The changes to healthcare in the Affordable Care Act, providing efficient, cost
effective care will be crucial factors in the primary care setting. Reimbursement will be
associated with patient outcomes and the quality of care provided.
Properly prescribing treatments for pain control improves delivery of healthcare
and outcomes for patients with chronic pain. Increasing education of healthcare providers
should ensure that providers properly prescribe prescription opioid pain medications and
give prescribers a better understanding of how prescription opioid pain medications can
be misused (Drug Abuse, 2013). Accessing the PDMP allows prescribers to be informed
on prescriber-shopping behaviors in patients with complaints of chronic pain and allow
prescribers to make proper decisions when prescribing treatments for pain control. As
patients present to the primary care settings with complaint of chronic pain, prescribers
should be utilizing evidence-based practice guidelines as well as the PMDP to guide
treatment of chronic pain.
Deaths from prescription opioid pain medication misuse have steadily increased
over the past decade. Many states have implemented prescription drug monitoring
programs to assist in combating the problem of prescription drug misuse. Prescribers in
the primary care health care clinic include physicians and nurse practitioners. Nurse
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practitioners that are prepared with a practice focused doctorate degree, the Doctor of
Nursing Practice (DNP), are prepared to lead change in practice setting through
organizational and systems leadership for quality improvement. Using the Plan Do Study
Act (PDSA) model for quality improvements, this capstone project will show continuous
improvements in the quality of patient outcomes while minimizing the risk of
prescription drug misuse. Evaluating and implementing evidenced-based protocols to
minimize the risk of prescription opioid pain medications is within the scope of practice
of a DNP prepared nurse practitioner. This capstone project conducted by a family nurse
practitioner (FNP) in a DNP program will focus on providers in a primary health clinic
in the state of Mississippi and determine if the providers are utilizing EBCP guidelines
including accessing the PDMP to minimize the risk of opioid pain medication misuse by
patients with a diagnosis of chronic pain.
Needs Assessment
While working as a FNP in a community based primary care setting in central
Mississippi, several patients presented to the clinic with complaints of chronic pain
requesting prescriptions for opioid pain medications. A survey of providers, physicians
and nurse practitioners, revealed similar experiences with no clear directions on
prescribing of opioid pain medications, leaving prescribers to rely on clinical judgments
and past experiences. Although the state of Mississippi has an active PDMP, most
providers at the clinic were not registered with the PDMP, or if registered, were not
accessing the reports. There were also no clear evidence-based guidelines for prescribing
opioid pain medication in the clinic; therefore, prescriber were left to use their clinical
knowledge and expertise.
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Further evaluation included reviewing, over a 12 month period, medical records
of patients who presented to the clinic with reports of chronic pain using diagnosis codes
338.2 (chronic pain), 338.21 (chronic pain due to trauma), and 338.29 (other chronic
pain) who received a prescription from a provider for opioid pain medication. The 12
month review revealed 125 patients who had a diagnosis of chronic pain and were
prescribed an opioid pain medication. Of the patients with a diagnosis of chronic pain the
distribution of males and females were essentially equal (n=62 males; 49.6% and n=63
females; 50.4 %). Forty-two or approximately 34% of the patients were between the ages
of 45-54 years of age. The results of the medical review was presented to the key
stakeholders of the organization who agreed to proceed with the implementation of
educating the providers on using evidenced-based protocols to treat patients with chronic
pain seen in the primary care clinic to minimize the risk of prescription opioid pain
medication misuse. As a DNP student and full-time prescriber in the clinic,
implementing the evidence-based protocols would improve the quality of patient
outcomes in the clinic. While providing education on EBCP guidelines for prescribing
opioid pain medications for chronic pain, prescribers’ attitudes toward using the PDMP
were explored and barriers to use were identified. Steps to alleviate the barriers to
accessing the PDMP were put in place. The results of the educational intervention were
presented to the medical director and approval was obtained to determine providers’ use
of the PDMP and the impact of accessing the PDMP on proper prescribing of opioids.
The problem. As patients seek care in primary care settings with complaints of
chronic pain, healthcare providers’ first thoughts are to treat the patient with a
prescription for an opioid pain medication. Sometimes this will lead to repeat offenders
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returning multiple times with similar or the same complaints looking for continued
prescription refills of opioid pain medication. Every effort should be made to find
alternative treatments, especially when patterns are noted. A comprehensive history
including accessing the PDMP should be taken and a complete physical examination
should be conducted to ensure proper prescribing. It is important that patients receive
pain-relieving medications when needed, with proper dosing (beginning with the lowest
dose and titrating for pain relief) and quantities (Fishman, 2012).
The DNP prepared nurse practitioner should be ready to take on the problem-of
prescription drug misuse and work with others in the health care arena to devise
solutions, formulate plans and guidelines, and come to the table to have changes
implemented. Once a systematic review of the literature is conducted, evidence-based
guidelines can be implemented to improve patient and system outcomes. For this DNP
project, the PICOT question to be addressed was: In patients that present to a primary
care clinic with a diagnosis of chronic pain and request prescriptions for opioid pain
medications, how does accessing the PDMP and utilizing evidence-based guidelines prior
to prescribing treatment compared to not using the PDMP and evidence-base guidelines
minimize the risk of opioid misuse?
Relevant Review of the Literature
Data sources accessed for this study include the following databases: CINAHL,
Cochrane Database, MEDLINE, PsycARTICLES, PsychINFO and evidence-based
treatment guidelines. Key terms used in the review of the literature were: opioid pain
medication, PDMP, chronic pain, provider prescribing habits, evidence-based guidelines,
mitigation strategies
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Prescription drug monitoring programs. In a systematic literature review of
eleven peer reviewed research articles, an investigation of Prescription Drug Monitoring
Programs (PDMPs) use, implications to practice, and barriers were explored (Worley,
2012). In this study eleven peer reviewed research articles were identified and reviewed.
The researcher identified four themes: PDMPs effect on prescribing opioids, PDMPs
effects on prescribing benzodiazepines, multiple provider use and patient characteristics,
and healthcare professional’s perspectives on PDMPs (Worley, 2012). On conclusion of
the review it was noted that are few research studies done on this subject (Worley, 2012).
It was confirmed that the use of PDMPs limits doctor shopping and reduces prescription
drug misuse (Worley, 2012). Further research is needed to determine the frequency that
prescribers use PDMPs, barriers to its use, and what interventions would increase usage
of PDMPs (Worley, 2012).
In a study performed by Reigler et.al, the question was asked whether prescription
drug monitoring programs impact opioid misuse. In this observational study data from a
poison center and an opioid treatment center were used to observe whether there were
changes in the surveillance data after implementation of a prescription monitoring
program (Reigler et al., 2012). The result of the study showed PDMPs are effective in
decreasing prescription opioid misuse (Reigler et al., 2012). The data showed the
increase of intentional exposures and also the increase of admissions to treatment centers
to be much lower in states where PDMPs had been implemented (Reigler et al., 2012).
In a briefing on PDMP performed by the PDMP Center of Excellence at Brandeis
University, concluded that the use of PDMPs are effective in improving clinical decision
making and improved patient outcomes ("Briefing on PDMP," 2014). The revised
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version of the briefing contained over 60 references that includes research studies,
evaluations, surveys, reports, and data to support these conclusions ("Briefing on
PDMP," 2014). The briefing also states that the PDMP will become more effective as
prescribers continue to use evidence-based best practices ("Briefing on PDMP," 2014).
Treatment modalities for chronic pain. The Institute for Clinical Systems
Improvement (ICSI) provided recommendations for improved treatments for patients
with complaints of chronic pain (Hooten et al., 2013). According to the
recommendations it is important to look at the problem of prescription drug misuse from
a clinical as well as an operational viewpoint (Hooten et al., 2013). Processes should be
developed to allow patients to see dedicated prescribers who should work collaboratively
with other healthcare providers, such as dentists and specialists to coordinate care
(Hooten et al., 2013). Policies should be implemented to monitor and maintain opioid
agreements prior to prescribing an opioid pain medication (Hooten et al., 2013).
Education to prescribers for referring patients to other disciplines such as pain
management clinic should be implemented (Hooten et al., 2013). According to the ICSI
chronic care teams that include prescribers, pharmacy, behavioral health, physical
therapy, and pain management should also be implemented when treating patients with
complaints of chronic pain (Hooten et al., 2013). While patients should have a pain
assessment conducted prior to providing treatment for pain relief, the goal of treatment
should be the improvement of overall functioning, not simply to give pain medication
(Hooten et al., 2013). Examples of tools to assess for pain and functioning may include
the Brief Pain Inventory (BPI) or the Physical Functional Ability Questionnaire (FAQ5)
(Hooten et al., 2013).
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Prescription drug misuse and abuse recognition. Obtaining a good history and
physical is one of the major determinants of risk for misuse of opioid pain medications
(FSMB, 2004; “Guidelines for prescribing opioids”, n.d.). Obtaining the history and
physical can clue a prescriber into past history of misuse. The history should include a
past medical, family/social and past medical history including history of mental health
problems and substance abuse. (“Guidelines for prescribing opioids”, n.d.). Assessing
the nature and intensity of pain, assessing the effect of pain on daily functioning and
quality of personal life, also assessing the past history of opioid use are all areas to alert a
prescriber into clues for possible risk of misuse (Fishman, 2012). Any comorbid
conditions should be identified as well as psychological and mental health histories
(Fishman, 2012). Obtaining the complete and thorough history and physical could lead
to improved identification of patients at risk for prescription opioid pain medication
misuse.
Culberson and Ziska (2008) studied the misuse of prescription drugs in the elderly
by reviewing the literature of studies previously reported. Unsafe amounts of
medications obtained by older adults are usually not obtained for the reasons of “getting
high”, but instead by seeking prescriptions from multiple physicians or doctor shopping,
by stockpiling medications over a period of time, (Culberson & Ziska, 2008). Therefore
prescription drug abuse for the elderly is different than for younger persons (Culberson &
Ziska, 2008). According to Culberson and Ziska (2008) there is not a validated screening
instrument designed to identify or assess for prescription drug abuse in the elderly.
Although they did look at the Severity of Dependence Scale for use as a screening
instrument for benzodiazepine dependence when looking at elderly patients who use
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benzodiazepines (Culberson & Ziska, 2008). Elderly patients with symptoms such as
anxiety, pain, and insomnia are at risk for prescription drug abuse, although illicit drug
use is rare among the elderly (Culberson & Ziska, 2008). Other causes of misuse/abuse
can be contributed to inappropriate prescribing or poor monitoring by health care
professionals (Culberson & Ziska, 2008). It is generally uncommon for prescription drug
abuse among elderly patients who have no history of substance abuse problems
(Culberson & Ziska, 2008). This study of 565 geriatric psychiatric patients concluded
that elderly individuals with social isolation, depression, and history of substance abuse
are at increased risk of prescription drug abuse (Culberson & Ziska, 2008). It also notes
that the development and validation of screening instruments and treatment guidelines for
prescription drug abuse in the elderly may aid in the appropriate use of prescription
medications (Culberson & Ziska, 2008).
Prescribing opioid pain medication. In a cohort study by Dunn et al., pharmacy
data were obtained and medical records were reviewed and analyzed to study estimated
rates of opioid overdose. This study sought persons who received 3 or more opioid
prescription for noncancerous pain within a ninety day period (Dunn et al., 2010). The
authors selected 9940 people who started long-term opioid therapy and followed them for
forty-two weeks (Dunn et al., 2010). Of those who were selected in the study, 61% of the
participants completed the study, 32% left during the study, and 7% died (Dunn et al.,
2010). There were six fatal opioid-related overdoses and 74 non-fatal overdoses during
the study (Dunn et al., 2010). Dunn et al. found the overdose rate for persons 65 years
and older was greater than the overdose rate of younger adults (Dunn et al., 2010). The
results of the study showed patients receiving higher doses of prescription opioid
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medications in higher doses were at a higher risk of overdosing than persons receiving a
lower dosage (Dunn et al., 2010). Although there were limitations to the study it could
not be established whether overdose risk differences were directly related to dosages or
patient characteristics (Dunn et al., 2010). Dunn et al. states further studies are needed to
understand the specific determinants of overdose risk in patients receiving long-term
opioid therapy (Dunn et al., 2010). It also suggests that persons receiving long-term
opioid therapy should be closely monitored and careful instructions on appropriate use of
medications (Dunn et al., 2010).
The Centers for Disease Control and Prevention, the National Center for Injury
Prevention and Control, along with the National Institute on Drug Abuse (NIDA) and the
Substance Abuse and Mental Health Services Administration (SAMHS), and the Office
of the National Coordinator for Health Information Technology (ONC), together
reviewed and compared eight guidelines to identify common areas for recommendations
for prescribing opioids for chronic pain (CDC, n.d.). Common elements found in all
eight guidelines include:
•

Conducting a physical exam, pain history, past medical history, and
family/social history

•

Conducting urine drug testing

•

Considering all treatment options, weighing the risks and benefits of
prescribing opioids

•

Starting patients on the lowest effective dose

•

Implementing pain treatment agreements

•

Monitoring pain and treatment progress with documentation
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•

Using safe and effective methods for discontinuing opioids (CDC, n.d.,
para. 6).

In a systematic review by Nuckols et al. (2014), guidelines were screened for
prescribing opioids utilizing an appraisal of 1132 unique records. Recommendations
from 13 guidelines were abstracted assessing dosing limits, medications and
formulations, titration of dose, switching from one opioid to another, drug-to-drug
interactions, and risk mitigation strategies (opioid risk assessment tools, written treatment
agreements, and urine drug testing). Thirteen guidelines on using opioids to treat chronic
pain were evaluated for quality related to mitigating risks for overdose and misuse
(Nuckols et al., 2014). Although the guidelines were derived from various clinical
emphasis and backgrounds, common themes emerged from the evaluation (Nuckols et al.,
2014). The guidelines generally agreed on the following issues: need for caution in
prescribing doses greater than 90 to 200 mg of morphine equivalents per day, having
knowledgeable clinicians when managing methadone, recognizing risks associated with
fentanyl patches, titrating with caution, and reducing doses by 25-50% when switching
from one opioid to another (Nuckols et al., 2014).
Guidelines for prescribing opioids established by the Federation of State Medical
Boards (FSMB) state a medical history and physical must be obtained, evaluated, and
documented in the medical record when prescribing opioids (FSMB, 2004). The
guidelines state there should be a written treatment plan with objectives to determine
treatment success, such as improved physical functioning (FSMB, 2004). Once opioids
are prescribed, the prescriber should adjust drug therapy to each patient’s individual
needs, which could include other treatment modalities such as a rehabilitation program
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(FSMB, 2004). The prescriber should periodically review the patient’s treatment plans
and their progress towards the objectives and modify treatment as needed (FSMB, 2004).
If progress is unsatisfactory, the prescriber should assess the appropriateness of the
current treatment plan and consider other therapeutic modalities (FSMB, 2004).
Prescribers should be willing to refer patients for additional evaluations and treatments
for the management of their chronic pain (FSMB, 2004). The medical record should
include the following:
•

Medical history and physical

•

Diagnostic, therapeutic, and laboratory results

•

Evaluations and consultations

•

Treatment objectives

•

Discussion of risks and benefits

•

Informed consent

•

Treatments

•

Medications

•

Instructions and agreements, and

•

Periodic reviews. (FSMB, 2004)

Risk mitigation strategies. Risk mitigation strategies should be implemented when
prescribing opioid pain medications. Risk assessment tools should be used, written
treatment agreements should be obtained, and urine drug testing would be helpful when
prescribing opioids (FSMB, 2004; Nuckols et al., 2014). The Screener and Opioid
Assessment for Patients with Pain (SOAPP) is a tool used by prescribers to help
determine a patient’s risk for long-term opioid use ("SOAPP," 2008). The SOAPP is a
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questionnaire developed to assist prescribers in evaluating patients for relative risk of
developing problems from long-term opioid use ("SOAPP," 2008). Patients can be
categorized into three different groups based on their SOAPP scores (low, medium, or
high) showing their relative risk for problems when being prescribed opioid pain
medications ("SOAPP," 2008). It is also noted that the SOAPP is a tool to assess the risk
of opioid pain medication misuse and not a lie detector and there may be false positives
("SOAPP," 2008). Other tools that assess for risk include the CAGE, Current Opioid
Misuse Measure (COMM), Screening Tool for Addiction Risk (STAR), and Webster’s
Opioid Risk Tool (ORT).
Informed consent and agreement for treatment should be obtained by the
prescriber with the risks and benefits of the use of opioid medications discussed with the
patient and/or the patient’s family (FSMB, 2004). Patients who are a high risk for misuse
should have a written agreement with the provider outlining the patient’s responsibilities
which may include drug screening when requested, number and frequency of all
prescription refills, and reasons for which drug therapy may be discontinued (FSMB,
2004; “Guidelines for prescribing opioids,” n.d., para. 6)
In summary the review of literature shows us that the PDMP and implementing
evidence-based guidelines are effective in minimizing the risk for prescription opioid
pain medication misuse. Prescribers should obtain thorough history and physicals to
assess the patients’ risk for misuse of opioid pain medications. To assist in assessing for
risk, the literature provides risk assessment tools such as the SOAPP or COMM that
should be used in combination with other evidence-based guidelines. The literature
suggest that inappropriate prescribing contributes to the increasing misuse of prescription
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opioid pain medications The literature shows that care coordination is another area that is
key in minimizing misuse of opioid pain medications. Prescribers should be willing to
make appropriate referrals to other providers such as physical therapy and mental health
providers when patients present to the primary health clinic with complaints of chronic
pain. This project will evaluate whether implementing evidence-based guidelines, as
shown in the literature review (Appendix A), by providers minimizes the risk for
prescription opioid pain medication misuse among patients with chronic pain in a primary
care setting.
Framework (Theoretical Background)
This project will utilize a portion of Deming’s 14 point model to guide the study.
The ability to use statistics to aide in the discovery of root causes to problems, and also to
create solutions to manage corrective measures are at the heart of Deming’s 14 points of
management. Deming’s theory creates the consistency for improvement of products and
services. The point utilized for this project refers to constantly and forever improve the
system of production and service ("The Fourteen Points for Management," 2015).
Deming proposed a continuous loop of identifying a problem, changing the process, and
re-assessing processes for continuous quality improvements ("The Fourteen Points for
Management," 2015).
As a framework, this project will use the Plan-Do-Study-Act to show the
continuous cycle of quality improvements. The “Plan” is to evaluate whether prescribers
are utilizing evidence-based guidelines which include assessing the PDMP prior to
prescribing opioid pain medication. The “Do” consists of the education of the providers
on prescription opioid drug misuse, the importance of using evidence-based guidelines
which include the PDMP when prescribing opioids, ensuring they are all signed up for
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the PDMP. “Study” is the evaluation of whether prescribers are utilizing evidence-based
guidelines prior to prescribing opioid pain medication, and “Act” is an evaluation for
further needs and the cycle starts over.
DNP Essentials
On completion of this capstone project, the DNP essentials are fully met and
listed in Appendix B (American Association of Colleges of Nursing [AACN], 2006). By
using evidence-based protocols to implement a change in the prescribing practices of
providers in a primary care community health center, the project seeks to minimize the
risk of misuse of opioid pain medications in patients with the diagnosis of chronic pain.
The use of EMR to access medical records for data gives knowledge of information
systems and technology which is essential for the DNP prepared advanced practice nurse.
Development of the project gave knowledge in organizational and systems leadership by
allowing the evidence-based protocols to be introduced to the community health clinic’s
staff and leadership. Introducing the providers to evidence-based healthcare policy
improves patient outcomes in the primary care setting and allows the DNP prepared
advanced practice nurse to develop strategies to enhance and evaluate healthcare
outcomes. Implementing the quality improvement project shows expertise in assessing
and identifying organizational and systems issues and facilitates organization-wide
changes in prescribing habits. Collaborating with key stakeholders and other providers in
the clinic to minimize the risk of prescription opioid pain medications aides in improving
patient outcomes. The results of this project will first be submitted to the organization for
quality improvements, then possibly other clinics to improve population health.
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Evaluation Plan
This project seeks to evaluate whether evidence based guidelines including the
Prescription Drug Monitoring Program (PDMP) are utilized by healthcare providers prior
to prescribing opioid pain medications in patients diagnosed with chronic pain. The
Logic Model in Appendix C demonstrates the evaluation plans for this project.
Assumptions. The assumption is that once educated providers will change their
current prescribing habits and adopt more evidence-based practices. It is also assumed
that once these guidelines are followed the risk of patients misusing prescription opioids
would be minimized by prescribers obtaining thorough history and physicals, obtaining
informed consent, urine drug screens, and also accessing the PDMP.
Purpose of the project. The purpose of this doctoral capstone project is to
determine if providers are accessing the PDMP and utilizing evidence-based guidelines to
minimize opioid pain medication misuse among patients with chronic pain in a primary
care setting.
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CHAPTER II
METHODS
The purposes of this doctoral capstone project is to determine if healthcare
providers are accessing the PDMP and utilizing evidence-based guidelines to minimize
opioid pain medication misuse among patients with chronic pain in a primary care
setting. The project was implemented after receiving approval from the Institutional
Review Board (IRB) at the University of Southern Mississippi (Appendix D).
Setting
The capstone project was conducted in a primary care clinic which serves patients
across the lifespan, from infants to older adults. This clinic is located in an urban
metropolitan area in central Mississippi and serves patients with all types of health
insurance, but a majority of the patients are covered under Medicare and Medicaid.
Uninsured patients are also seen and billed for healthcare services according to a sliding
scale payment plan. This clinic is a Federally Qualified Health Clinic which exists to
provide healthcare to underserved populations. The patient base consists of
approximately 60% females and 40% males. The racial/ethnic make up for the
population of this community health clinic-up consists of 94% African Americans, 5%
Caucasians, and 1% Hispanic or other.
There are a total of 45 full-time employees and 2 part-time contract employees.
Of the 47 employees, the clinic employs a total of 13 providers that can prescribe
medications: 4 full-time and 1 contract nurse practitioners (NP); 1 full-time physician
assistant (PA); and 5 full-time physicians and 1 contract physician (Doctor of Medicine
[MD], and 1 Doctor of Osteopathy [DO]) . There are three different clinic locations that
fall under this one community health primary care clinic. Data from the EMR will be
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collected from all three locations. A letter of support from the organization has been
obtained prior to implementing the project (Appendix E)
Population
The subjects for this project comprise a convenience sample of healthcare
providers, (physicians, nurse practitioners, and physician assistants) who prescribe an
opioid pain medication and provide healthcare to patients between the ages of 45 thru 54
years of age who have a diagnosis of chronic pain. The project included a review of
medical records completed by prescribing providers (MD, DO, PA, NP).Male and female
patients were identified to include in the project using the Ninth revision of International
Classification of Disease (ICD-9) diagnoses codes 338.2 (chronic pain), 338.21 (chronic
pain due to trauma), and 338.29 (other chronic pain). Patients 44 years of age and
younger or 55 years and older and diagnosed with other types of pain (such as back or
neck pain) without a diagnosis code of chronic pain were excluded due to the needs
assessment shows the greatness number of patients who presented to the clinic with the
diagnosis of chronic pain fell between the ages of 45 to 54 years of age. For the purpose
of this project, prescribing providers’ progress notes in the electronic medical record
(EMR) of patients that meet inclusion criteria were accessed by retrospective chart
review. The number of records accessed was determined by the number of patients that
may present for services during the data abstracting time period.
Design
The design of the project is descriptive. This project consisted of a retrospective
chart review of prescribers’ documentation in the medical record to determine if the
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PDMP was accessed and if evidence-based protocols were used when prescribing opioid
pain medication to patients diagnosed with chronic pain.
Procedures
After obtaining USM IRB approval, a systematic retrospective medical record
chart review was conducted to determine whether prescribing providers access the PDMP
and use evidence-based guidelines prior to prescribing opioid pain medications to
patients with complaints of chronic pain. The project director was a full-time prescriber,
family nurse practitioner (FNP), at the community health primary care clinic. Prior to
conducting the retrospective chart review, informed consent was obtained by the Project
Director (PD) from the provider participants to access and report documentation of
evidence-based guidelines in records of patients seen with a diagnosis of chronic pain.
After the PD obtained provider consent, the trained data abstractor conducted a
retrospective chart review to determine whether prescribing providers access the PDMP
and use evidence-based guidelines to minimize a patient’s risk for prescription opioid
pain medication misuse in a community health primary care setting. The data abstractor
is a full-time prescriber, family nurse practitioner (FNP), at the community health
primary care clinic.
Electronic medical records (EMR) were accessed by the trained data abstractor
who is employed at the community health primary care clinic. Training and education
was provided by the PD on documentation that should be included in the medical record
when prescribing opioids. Records were abstracted from the selected timeframe of
October 1 thru December 31 2014 of patients who presented to the clinic and meet
inclusion criteria for data collection. Subject selection was based on patient’s age 45 to
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54 years with the diagnosis of chronic pain using the ICD-9 diagnoses codes of 338.2,
338.21, and 338.19 during the three month timeframe (Centers for Medicaid and
Medicare Services [CMS], n.d.).
EMR access. After logging in to the EMR using a unique protected password, the
trained data abstractor, an employee of the clinic, generated a report of patients that met
inclusion criteria. The report query was generated by going to the reports menu. Once the
reports menu was accessed, the data abstractor entered the reporting criteria, (the age of
the patients [age 45-54 years], the reporting period [October 1 2014 thru December 31,
2014], and the diagnoses codes [338.2, 338.21, 338.19] to be associated with each record
as described above). When the criteria were entered the generate report tab was used to
create a list of patient records that meet the given criteria. The report, although generated
at the main clinic, provided information on patients from all three clinics. Once the report
was generated, the trained data abstractor printed the report to identify records that were
accessed for data extraction. Each patient on the list was assigned a unique identification
(ID) number. The identification number was coded on the data collection form (Appendix
B). The report with the names of patients that meet inclusion criteria and the data
collection form with ID numbers will be kept in a lock drawer in the data abstractor’s
office at the clinic. During data collection, the patient’s medical record was accessed
from the list of patients that meet inclusion criteria by entering the patients’ name into the
EMR.
EMR documentation. Once the progress note in the patient’s record was accessed
the most recent visit/encounter was reviewed for extraction of whether evidence-based
guidelines were utilized including accessing the PDMP. The progress note is the only
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section of the EMR that was evaluated for documentation of accessing the PDMP and
whether evidence-based guidelines were utilized. Using a data extraction tool (Appendix
F) with the patient ID number that matches the ID number on the query report, the most
recent visit/encounter’s progress note was assessed for the type of prescribing provider
(MD, DO, PA, NP) that delivered health care to the patient, documentation of whether
the prescriber obtained a complete history and physical, accessed the PDMP, obtained a
urine drug screen, and had the patient sign an informed consent/patient agreement. The
nature of pain, intensity of pain, past treatment for pain, co-existing medical conditions,
effect of pain on physical functioning, and past history of substance abuse were evaluated
in the history and physical documentation. The informed consent was evaluated to
determine if patient education on risk and benefits of use, an agreement for use of opioids
and reason(s) for discontinued prescribing of opioids were documented. The progress
note was reviewed to evaluate whether the risk of misuse is minimized as evidence by
prescribing providers documentation of whether an opioid pain medication was
prescribed; an opioid pain medication dose was lowered; a referral to any other
disciplines such as physical therapy or pain management was generated; goals are clearly
identified in the medical record; and education was provided.
Data collection. No identifying information will be recorded on the data
collection form. Confidentiality of the data were maintained by the utilization of
identification numbers (ID) instead of names. Each question was numbered with a
dichotomous response. A “yes” answer will be coded as “1”, a “no” answer will be coded
as “2”. Once the information was collected on the data collection tool, the results were
documented in an excel spread sheet using codes for each variable. Review and analysis
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of de-identified existing data were performed using SPSS procedure crosstabs which is a
chi square statistical analysis program. Data were stored under double locks in the office
of the trained data abstractor in the clinic by which only the data abstractor had access.
Ethical protection of human subjects. The project consisted of a retrospective
chart review with no identifying information. Data were extracted by the data abstractor
directly from the progress note in the EMR and no records were printed or copied. Data
were recorded and summarized by the trained data collector so that subjects cannot be
identified, directly, or through identifiers linked to the subjects. To ensure confidentiality
and anonymity, subjects’ information was protected through the use of codes assigned by
the data abstractor on a data collection form. Data on the generated report and data
collection tool were stored under double locks in the office of the trained data abstractor
in the clinic by which only the data abstractor had access. The data collection tools were
placed in an envelope by the data abstractor and given to the project director (PD) for
analysis and completion of the project. Data entered on the data collection tool did not
contain any identifying information. Information on the data collection tool was entered
into an Excel spreadsheet by the PD in order to maintain confidentiality. Data were
stored on a password protected computer. Confidentiality was protected by placing the
data collection tools in a locked file box that was be kept in the office of the PD and only
the PD had access to the locked file box and drawer.
There were minimal risks of harm to subjects associated with this project. The
project consisted of a retrospective chart review. The primary subjects are the health care
providers, and data on documentation in the patient's EMR was reported in aggregate, no
single person was identified. Data are anonymous via de-identification and was protected
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using coding, and cannot be associated with individual subjects; therefore, loss of privacy
and breach of confidentiality was not a risk. Although the project director knows who the
providers are, the association of providers to which data were not accessible. Providers
who agreed to participate may fear occupational consequences if they do not participate,
but were assured of no consequences for not participating on the consent given prior to
participation. Benefits of this project are to improve evidence-based prescribing
practices among healthcare providers and minimize opioid pain medication misuse
among patients with chronic pain in a primary care setting.
Data Analysis
Data were retrieved through a review of the medical records and extracted using a
collection tool created to look at indicators of whether evidence-based protocols are
present in the documentation. Dichotomous variables were collected and coded.
Information collected with the data extraction tool was entered into an Excel spreadsheet
using a unique index identifier to prevent duplication. The answer to each question was
coded and entered into the spreadsheet. Once the data collection was completed, the
information was analyzed using SPSS procedure crosstabs which is a chi square to
determine if prescribers are utilizing evidence-based guidelines to minimize risk of
opioid pain medication misuse. Chi square testing was utilized due to the dichotomous
“yes” or “no” answers to the data collection tool to count the categories of responses.
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CHAPTER III
RESULTS
The purpose of this doctoral capstone project was to determine if providers are
accessing the PDMP and utilizing evidence-based guidelines to minimize opioid pain
medications misuse among patients with chronic pain in a primary care setting. Seven
(N=7) records were identified which met inclusion criteria for the project, patients who
presented to the primary care clinic with the diagnosis codes of 338.2 (chronic pain),
338.21 (chronic pain due to trauma), and 338.29 (other chronic pain) and age range
between the ages of 45-54 years. Seven providers (3 physicians, 3 nurse practitioners,
and 1 physician assistant) consented to have medical records reviewed of patients that
were seen that met inclusion criteria. All records abstracted were records that were
documented by the 3 nurse practitioners. The physician assistant and physicians did not
have any records that met the criteria for inclusion in the study.
The most recent visit/encounter’s progress note was assessed for the type of
prescribing provider (MD, DO, PA, NP) that delivered health care to the patient,
documentation of whether the prescriber obtained a complete history and physical,
accessed the PDMP, obtained a urine drug screen, and had the patient sign an informed
consent/patient agreement. The history and physical documentation includes the nature of
pain, intensity of pain, past treatment for pain, co-existing medical conditions, effect of
pain on physical functioning, and past history of substance abuse. The informed
consent/patient agreement consists of patient education on risk and benefits of use, an
agreement for use of opioids and reason(s) for discontinued prescribing of opioids. The
progress note was also reviewed to evaluate whether the risk of misuse is minimized as
evidence by prescribing providers documentation of whether an opioid pain medication
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was prescribed; an opioid pain medication dose was lowered; a referral to any other
disciplines such as physical therapy or pain management was generated; goals are clearly
identified in the medical record; and education was provided. The data collection was
completed and analyzed using chi square distribution.
History and Physical. All (N=7; 100%) of the charts had a history and physical
documented by the providers in the medical record that included the nature of pain,
intensity of pain, past treatments of pain, co-existing, and effects of pain on physical
functioning . As seen in table 1 below the majority of the records (n=6; 87.5%) had no
documentation of past substance abuse.
Table 1
History and physical
Variables

Frequency

Percent

History and
Physical

Yes

7

100.0

Nature of
pain

Yes

7

100.0

Intensity of
pain

Yes

7

100.0

Past pain
treatments

Yes

7

100.0

Co-existing
conditions

Yes

7

100.0
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Table 1 (continued).
Variables

Frequency

Percent

Effect of
pain on
physical
functioning

Yes

7

100.0

Past history
of substance
abuse

Yes

1

14.3

No

6

85.7

Prescription Drug Monitoring Program. Documentation of accessing the
Prescription Drug Monitoring Program (PDMP) prior to prescribing opioid pain
medication was not documented by providers most (n=5; 71.4%) of the time.
Evidence-Based Guidelines. Table 2 shows the results of whether evidence-based
guidelines were followed to minimize risk for opioid pain medication misuse. All (N=7;
100%) of the charts were missing documentation of obtaining a urine drug screen prior to
prescribing an opioid pain medication and more than half (n=4; 57.1%) of the charts were
missing documentation of an informed consent/patient agreement. When patients
presented to the clinic with complaints of chronic pain, patients were prescribed an opioid
pain medication by the provider less than half (n=3; 42.9%) of the time and if prescribed
(N=3; 100%) the dose was not lowered. The majority of the charts reviewed indicated
that patients were referred to another discipline (n=4; 57.1%); goals were identified to
improve functioning (n=5; 71.4%), and education on safety (n=4; 57.1%) was provided.

35
Table 2
Evidence-based guidelines
Variables

Frequency

Percent

Yes

2

28.6

No

5

71.4

Informed consent/

Yes

3

42.9

Patient Agreement

No

4

57.1

Urine drug screen

No

7

100.0

Was an opioid prescribed?

Yes

3

42.9

No

4

57.1

Was opioid dose lowered?

No

7

100.0

Was patient referred to
other discipline?

Yes

4

57.1

No

3

42.9

Yes

5

71.4

No

2

28.6

Yes

4

57.1

No

3

42.9

PDMP accessed

Were goals clearly
identified?
Was education
documented on safety?
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CHAPTER IV
DISCUSSION
The misuse of opioid pain medications has become an epidemic in the United
States. Federal and state governing bodies have implemented evidenced-based guidelines
which include accessing the Prescription Drug Monitoring Programs (PDMP) to aide in
minimizing opioid pain medication misuse. This capstone project was implemented to
evaluate the use of evidence-based guidelines by providers in a primary care setting.
While the data shows overall implementation of the guidelines, there is still room for
improvement. Although providers are indeed showing great efforts in thoroughly
documenting the history and physicals, documentation of the past history of drug abuse
has not shown to be an area where the prescribers have documented consistently. The
past history of substance abuse should be clearly documented as part of the medical
records prior to prescribing opioid pain medications (FSMB, 2004). A patient’s history
of substance abuse should aide a prescriber in recognizing whether a patient is at risk of
misuse of opioid pain medications. Accessing the PDMP is an area where it shows the
prescribers are not consistent. The analysis shows that the PDMP was only accessed and
documented 28.6% of the time. When prescribing opioid pain medications, the PDMP
should be accessed to aide in recognizing misuse.
While a history of drug abuse was not consistently assessed when conducting a
medical history, a urine drug screen was not documented as being performed prior to
prescribing an opioid pain medication in any of the medical records reviewed. Consistent
documentation of evidence-based guidelines was lacking in the chart review. The results
of whether there was an informed consent/patient agreement which gives the patient
education on risks, benefits, agreements for use, and reasons why the
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prescriptions may be terminated, according to the data analysis, was documented 42.9%
of the time. According to evidence-based guidelines, an informed consent should be
signed by the patient and provider when prescribing opioid pain medications.
Other the other hand, the majority of the charts reviewed showed documentation
of some of the evidence-based guidelines. Patients were referred to another discipline.
Referring patients to other disciplines such as physical therapy and pain management is
one step that will assist in minimizing the patient’s risk for misuse of opioid pain
medication. According to national guidelines from the Federation of State Medical
Boards, goals for functioning levels should be clearly identified when prescribing opioid
pain medications (FSMB, 2004). The study shows that in 71.4% of the medical records
were identified to have documentation of goals to improve functioning. Education on
safety was identified in 57.1% of the medical records abstracted during this project.
When prescribing opioid pain medications, each patient should be educated on the risks
of taking opioid pain medications for extended periods of time and given alternative
treatments and timeframes of weaning off the medications.
Prescribers should also attempt to lower the dosages of opioid pain medications of
patients with complaints of chronic pain. When patients presented to the clinic with
complaints of chronic pain, 42.9% of the time they are prescribed an opioid pain
medication and the dose was not lowered when prescribing opioids. Although the
statistics may seem a little alarming, there were some limitations to the project.
Limitations. Some of the limitations noted for this study include the small sample
size and the staff turnover rate. Although 13 providers were educated, only seven
providers consented to have their medical records reviewed. During the project the clinic
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had resignations from two prescribers. With the decrease in the prescribing staff during
the project, there is the potential that fewer patients were seen during the three month
time frame for the project. These changes may have played a part in the small sample
size. The small sample size is also hypothesized to have contributed to possible
procedures for coding the diagnosis. The diagnoses codes for chronic pain 338.2, chronic
pain due to trauma 338.21, or other trauma 338.29 were identified for this project. It is
unknown if other pain diagnoses codes were used by providers that apply to the particular
areas of the body such as back pain or leg pain. Other limitations to the study include the
cost of urine drug screening, especially in a community health clinic. Urine drug testing
for screening purposes may not be covered by insurance companies and providers may be
reluctant to order urine drug screens due to the cost of testing. Prior to beginning the
capstone project, discussions were held with the prescribers regarding the proposed goals
of the project and the idea of medical records review. This may have alerted the
prescribers to the possibility of their records under review and increased compliance with
utilizing the evidence-based protocols. The increase in compliance with utilizing
evidence-base protocols prior to prescribing an opioid pain medication was a goal for this
project overall.
Framework. Using the Plan-Do-Check-Act for continuous quality improvements
showed to be beneficial in guiding this study. Deming’s theory of using statistical data to
show root causes to problems and create a solution helped to guide this project in
showing whether the providers were utilizing evidence-based guidelines to minimize the
risk of opioid misuse. The theory of constantly and forever improving systems shows us
that the improvements needed do not stop at this project. The evaluation plan proves
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there is still work to be done. This is an ever evolving quality improvement plan to look
at improving patient outcomes and also decreasing healthcare as well as societal costs.
Implications for practice. The implications for future practice are to increase
providers’ awareness of evidence-based guidelines when prescribing opioid pain
medications. The results of this project will be shared with the key stakeholders of the
primary care community health clinic where this project was performed with suggestions
for implementing evidence-based guidelines for proper prescription opioid pain
medication prescribing. Implementation of evidence-based guidelines will be imperative
in the fight for minimizing risk of misuse of opioid pain medications. As prescribers are
educated and evidence-based guidelines are implemented, the risks of over-prescribing or
improper prescribing should show a decrease in misuse of opioid pain medications.
Recommendations for future research. Continuous process improvements in the
area of evidence-based protocols to minimize opioid pain medication should be in the
forefront of projects considered for future practice changes. Further studies should be
completed on whether proper prescribing habits actually decrease the misuse of opioid
pain medications. Further evaluations should be performed to assess the barriers to
utilizing evidence-based guidelines. The type of funding to assist with the effort to
combat opioid pain medication misuse is another area that should be further explored.
Insurance companies may not pay for urine drug screening in the clinic setting. Patients
may not want to pay to have a urine drug screening performed. Screening could become
a burden on the community health care clinic’s budget. As the problem of opioid pain
medication misuse has steadily increased over the past decades, DNP prepared nurse
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practitioners are equipped to research the evidence and implement protocols to minimize
risk and change practices.
Conclusions. This doctoral capstone project shows that the providers are
documenting components of the history and physical when patients present to a primary
care clinic with complaints of chronic pain. Past history of drug abuse and ordering urine
drug screens are evidence-based practice recommendations where prescribers have not
documented consistently. Accessing the PDMP is another area where it shows the
prescribers are not consistently documenting. Implementation of evidence-based
guidelines will be imperative in the fight to minimize risk of misuse of opioid pain
medications among patients with chronic pain in the primary care setting. Improving
prescribing habits to minimize prescription opioid drug misuse will show an
improvement in patient outcomes and lessen the societal burden of prescription drug
misuse in Mississippi and nationally. The DNP prepared advanced practice nurses will
be prepared to evaluate and implement ongoing process improvements to further improve
patient outcomes in a system that is associating reimbursement with the quality of care
provided, while also working to decrease the financial burden on the current healthcare
system.
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APPENDIX A
LITERATURE REVIEW TABLE

Authors date
Worley
(2012)

Study type
Literature
Review

Sample
Eleven peer
reviewed
research
articles were
used.

Culberson,
Ziska (2008)

Not a research
article

Elderly

Dunn, et.al.
(2010)

Cohort study

9940 patients
who received 3
or more opioid
prescriptions
within 90 days
for chronic
non-cancer
pain
Review of over
60 resources
and data

PDMP Center
of Excellence

Data collection Key findings
A critical
PDMP’s are
analysis of the
useful and
articles
necessary to
curb
prescription
drug abuse and
diversion.
More research
is needed to
determine the
frequency and
barriers to use
of PDMP’s.
Literature
Elderly are at
review
increased risk
of abuse of
certain
medications.
The
development
and validation
of screening
instruments
and treatment
guidelines for
prescription
drug abuse in
the elderly are
needed.
Pharmacy data Overdose
and medical
occurs at
records review increased rates
in patients
prescribed
opioids for
non-cancer
chronic pain.
Survey of 60
PDMPs are
references that
effective in
includes
improving
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Authors date

Study type

Sample
complied into a
report or
briefing

Data collection
research
studies,
evaluations,
surveys,
reports, and
data

Reigler, et.al.

Observational
study

Observed calls
to a poison
control center
and admissions
to a opioid
treatment
center

Quarterly
surveillance
data

Center for
Disease
Control and
Prevention

Evidence-based
guidelines

Federation of
States
Medical
Boards (2004)

Evidence-based
Guidelines

SM Fishman
(2012)

Evidence-based
guidelines

WM Hooten

A systematic

A review of
evidence based
guidelines

A literature

Key findings
clinical
decision
making and
improving
patient
outcomes.
PDMP will
become more
effective as
prescribers
continue to use
evidence-based
best practices
Shows the
increase of
intentional
exposures to
opioids and the
increase of
admission to
opioid
treatment
centers to be
much less in
states where
PDMPs had
been
implemented.
Common
elements of
different
evidence-based
guidelines
A policy for
use of
controlled
substances
when treating
chronic pain
A clinical
guideline for
responsible
opioid
prescribing
Guidelines
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Authors date
(2013)

Study type
review of
literature

Nuckols.
Et.al. (2014)

A critical
appraisal of
evidence-based
guidelines

Sample

Data collection
search using
PubMed and
Cochrane
databases

Key findings
were developed
to help primary
care providers
better diagnose
and treat pain.
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APPENDIX B
DNP ESSENTIALS
Essential
Scientific underpinning for practice

DNP Capstone
This project integrated nursing science
using analytical and organizational as the
highest level of nursing science with the
evaluation and implementation of
evidence-based guidelines to minimize
risk of prescription opioid pain
medications. Also evaluated and
implemented new practice approaches to
prescribing opioid pain medications to
improve outcomes of the patients.

Organizational and systems leadership for Implementing this project used advances
quality improvement and systems thinking processes to lead quality improvements
and patient safety initiatives in the clinical
setting. Employed health policy to
develop and implement effective plans for
system-wide practice by implementing
evidence-based guidelines to minimize the
risk of prescription opioid pain medication
misuse in a primary care clinic.
Clinical scholarship and analytical
methods for evidence-based practice

Analytical methods to critically appraise
existing literature and other evidence was
used to determine and implement the best
practice for prescribing opioid pain
medications. Quality improvement
methodologies were implemented to
promote safe, effective, and patientcentered care for prescribing of opioid
pain medications. Practice guidelines from
relevant findings were implemented to
improve practice.

Information system/technology for the
improvement and transformation of health

Demonstrated the conceptual ability and
technical skills to develop and execute
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care

and evaluation plan involving data
extraction from practice information
systems and databases. Provided
leadership in the evaluation of prescribing
habits of providers in the primary care
clinic relating to the use of information
technology and patient care technology.

Health care policy for advocacy in health
care

Critically analyzed health policy related to
prescription opioid pain medication
misuse. Demonstrated leadership in the
implementation of states and federal
guidelines for opioid pain medication
prescribing. Educated others on regarding
health policy and patient care outcomes.

Interprofessional collaboration for
improving patient population and
population outcomes

Employed effective collaborative skills in
the implementation of practice guidelines.
Employed leadership skills with
interprofessional teams to create change in
the health care delivery of patients who
present to the primary care clinic with
complaints of chronic pain.

Clinical prevention and population health
for improving the nation’s health

Analyzed epidemiological, biostatistical
and other scientific data related to
population health of patients who present
to the community health primary health
clinic with the diagnosis of chronic pain.
Synthesized concepts related to
population health in implementing and
evaluating interventions to address health
promotions to minimize risk of
prescription opioid pain medication
misuse in the primary care setting.

Advanced nursing practice

Conducted a comprehensive and
systematic assessment of prescribing
habits of the providers in a community
health primary care clinic. Demonstrated
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advanced levels of clinical judgment,
systems thinking and evaluating evidencebased care to improve patient outcomes.
Educated prescribers in evidence-based
guidelines to minimize risk of prescription
opioid pain medication misuse.
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APPENDIX C
LOGIC MODEL
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APPENDIX D
IRB APPROVAL LETTER

INSTITUTIONAL REVIEW BOARD
118 College Drive #5147 | Hattiesburg, MS 39406-0001
Phone: 601.266.5997 | Fax: 601.266.4377 | www.usm.edu/research/institutional.review.board

NOTICE OF COMMITTEE ACTION
The project has been reviewed by The University of Southern Mississippi Institutional Review
Board in accordance with Federal Drug Administration regulations (21 CFR 26, 111), Department
of Health and Human Services (45 CFR Part 46), and university guidelines to ensure adherence to
the following criteria:
• The risks to subjects are minimized.
• The risks to subjects are reasonable in relation to the anticipated benefits.
• The selection of subjects is equitable.
• Informed consent is adequate and appropriately documented.
• Where appropriate, the research plan makes adequate provisions for monitoring the data
collected to ensure the safety of the subjects.
• Where appropriate, there are adequate provisions to protect the privacy of subjects and to
maintain the confidentiality of all data.
• Appropriate additional safeguards have been included to protect vulnerable subjects.
• Any unanticipated, serious, or continuing problems encountered regarding risks to subjects
must be reported immediately, but not later than 10 days following the event. This should
be reported to the IRB Office via the “Adverse Effect Report Form”.
• If approved, the maximum period of approval is limited to twelve months.
Projects that exceed this period must submit an application for renewal or continuation.

PROTOCOL NUMBER: 15012801
PROJECT TITLE: Evidence-Based Strategies to Minimize Risk of Opioid Pain Medication Misuse
Among Patients with Chronic Pain in a Primary Care Setting
PROJECT TYPE: New Project
RESEARCHER(S): Carolyn Coleman
COLLEGE/DIVISION: College of Nursing
DEPARTMENT: Systems Leadership and Health Outcomes
FUNDING AGENCY/SPONSOR: N/A
IRB COMMITTEE ACTION: Expedited Review Approval
PERIOD OF APPROVAL: 01/28/2015 to 01/27/2016

Lawrence A. Hosman, Ph.D.
Institutional Review Board
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APPENDIX E
LETTER OF SUPPORT
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APPENDIX F
DATA COLLECTION TOOL
Identification Number ________________
Yes
History and Physical
Nature of pain
Intensity of pain
Past pain treatments
Co-existing conditions
Effect of pain on physical functioning
Past history of substance abuse
PDMP accessed
Informed Consent/Patient Agreement
Urine Drug Screen
Was an opioid prescribed?
Was opioid dose lower?
Was patient referred to other discipline?
Were goals clearly identified?
Was education documented on safety?
PROVIDER
MD contract
MD full-time
PA contract
PA full-time
NP contract
NP full-time

_____________________________

No
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